CINCINNATI, June 2, 2011 /PRNewswire/ -- Kendle (Nasdaq:
KNDL), a leading, global full-service clinical research
organization (CRO), today announced the appointment of Robert Shepard, MD, FACP, as Executive Director,
Oncology, Medical Affairs effective immediately. Dr. Shepard
is a leading authority on clinical development in oncology,
bringing more than four decades of oncology research experience to
Kendle. He will oversee the development of oncology programs for
customers worldwide, providing medical, safety and scientific
support to clinical research teams, investigators and customer
contacts.
"We are delighted Dr. Shepard has joined Kendle," said
Melanie A. Bruno, PhD, Vice
President, Regulatory and Medical Affairs. "His unsurpassed
experience and expertise will be invaluable to our customers as we
work with them to bring new oncology therapies to market."
Dr. Shepard has extensive research credentials in hematology and
oncology; is board certified in oncology, hematology and internal
medicine; and has a wide array of experience in translational
medicine and clinical research. He has been actively involved in
oncology research since 1970 and has been responsible for the
complete clinical development of several drugs and immune therapies
for biopharmaceutical companies, including serving as the
consulting Chief Medical Officer for six companies.
Dr. Shepard is a Magna cum Laude graduate of Harvard University in biochemical sciences and
molecular biophysics and studied in the Harvard-M.I.T. Health
Sciences program. He earned his medical degree from
Duke University in the Medical
Scientist Training Program, which included two years of graduate
training in immunology. Dr. Shepard completed a fellowship in
hematology and oncology at the Tufts-New England Medical Center
where he conducted laboratory research in leukemias, myeloma and
myelodysplasia. Dr. Shepard also completed a postdoctoral
fellowship in pharmacology and molecular genetics at the
Dana-Farber Cancer Center and Harvard Medical
School. He has held academic appointments at
Harvard University, Tufts University and the University of Virginia.
To meet Dr. Shepard at the American Society of Clinical Oncology
(ASCO) Annual Meeting June 3-7 in
Chicago and learn more about
Kendle's expertise in oncology clinical development programs,
please email info@kendle.com or contact us at +1 800 733 1572.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global
clinical research organization providing the full range of early-
to late-stage clinical development services for the world's
biopharmaceutical industry. Our focus is on innovative solutions
that reduce cycle times for our customers and accelerate the
delivery of life-enhancing products to market for the benefit of
patients worldwide. As one of the world's largest global providers
of Phase I-IV services, we offer experience spanning more than 100
countries, along with industry-leading patient access and retention
capabilities and broad therapeutic expertise, to meet our
customers' clinical development challenges.
For more information, please visit www.kendle.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements relating to Dr.
Shepard's anticipated contribution to programs for Kendle
customers. Words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "will," "should," "may," and other
similar expressions are intended to identify forward-looking
statements. Such statements are based upon the current beliefs and
expectations of Kendle's management and involve a number of
significant risks and uncertainties, many of which are difficult to
predict and are generally beyond the control of Kendle. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional factors that could cause
Kendle's results to differ materially from those described in the
forward-looking statements can be found in the periodic reports
filed with the Securities and Exchange Commission, which are
available at the Securities and Exchange Commission's website
(http://www.sec.gov) at no charge. Kendle assumes no responsibility
to update any forward-looking statements as a result of new
information or future developments except as expressly required by
law.
SOURCE Kendle International Inc.